Nursing a patient with latent autoimmune diabetes in adults with insulin-related lipodystrophy, allergy, and exogenous insulin autoimmune syndrome: A case report

Table 2 Configuration of insulin desensitization preparations

Time	Solution type	Dosage (mL)	Units (IU)	Adverse reactions
10:30	B	0.5	0.005	/
11:00	A	0.1	0.01	/
11:30	A	0.2	0.02	/
12:00	A	0.4	0.04	/
12:30	A	0.8	0.08	/
13:00	C	0.16	0.16	/
13:30	C	0.32	0.32	/
14:00	C	0.16	0.16	/
14:30	C	0.32	0.32	/
15:00	C	0.8	0.8	/
15:30	C	0.16	0.16	/
16:00	C	0.32	0.32	/
16:30	C	0.64	0.64	/
17:00	C	1.0	1.0	Mild itching, no wheals
18:00	Humalog 100 U/mL	2.0	/	Mild itching, no wheals
19:00	Humalog 100 U/mL	3.0	/	Patchy lesions on the skin at and beyond the injection site

A: Solution A at a concentration of 0.1 U/mL prepared with 0.1 mL of Humalog (100 U/mL) and 100 mL of NS; B: Solution B at a concentration of 0.01 U/mL prepared with 1 mL of solution A and 9 mL NS; C: Solution C at a concentration of 1 U/mL was prepared with 0.1 mL of Humalog (100 U/ mL) and 10 mL of NS.